Haynes W Sheppard

Summary

Affiliation: California Environmental Protection Agency
Country: USA

Publications

  1. ncbi request reprint HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion
    Haynes W Sheppard
    Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, California 94804, USA
    J Acquir Immune Defic Syndr 29:307-13. 2002
  2. ncbi request reprint Inactivated- or killed-virus HIV/AIDS vaccines
    Haynes W Sheppard
    California Department of Health Services, Richmond, 94804, USA
    Curr Drug Targets Infect Disord 5:131-41. 2005
  3. ncbi request reprint Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection
    Stephanie A Mulherin
    Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH DHHS, 6120 Executive Boulevard, Rockville, MD 20852, USA
    AIDS 17:377-87. 2003
  4. ncbi request reprint Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa
    Clive M Gray
    National Institute for Communicable Diseases, Johannesburg, South Africa
    AIDS Res Hum Retroviruses 21:285-91. 2005
  5. pmc Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection
    Tara M Riddle
    UNC Center for AIDS Research, University of North Carolina at Chapel Hill, CB 7295, Chapel Hill, NC 27599 7295, USA
    J Virol 80:10591-9. 2006
  6. ncbi request reprint Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
    Punnee Pitisuttithum
    Vaccine Trial Center, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    J Acquir Immune Defic Syndr 37:1160-5. 2004
  7. ncbi request reprint High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion
    Eleanor Gouws
    Medical Research Council, Congella, South Africa
    J Acquir Immune Defic Syndr 29:531-5. 2002
  8. pmc Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load
    Agatha Masemola
    National Institute for Communicable Diseases, Johannesburg, South Africa
    J Virol 78:3233-43. 2004
  9. ncbi request reprint Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Deborah Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 190:903-7. 2004
  10. pmc Breast milk pasteurization: appropriate assays to detect HIV inactivation
    Caroline J Chantry
    Infect Dis Obstet Gynecol 2006:95938. 2006

Research Grants

Collaborators

Detail Information

Publications17

  1. ncbi request reprint HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion
    Haynes W Sheppard
    Viral and Rickettsial Disease Laboratory, California Department of Health Services, Richmond, California 94804, USA
    J Acquir Immune Defic Syndr 29:307-13. 2002
    ..The pathogenic potential of these viruses may be different from late-stage X4 virus or early X4 virus acquired by individuals with other CCR5 genotypes...
  2. ncbi request reprint Inactivated- or killed-virus HIV/AIDS vaccines
    Haynes W Sheppard
    California Department of Health Services, Richmond, 94804, USA
    Curr Drug Targets Infect Disord 5:131-41. 2005
    ....
  3. ncbi request reprint Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection
    Stephanie A Mulherin
    Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH DHHS, 6120 Executive Boulevard, Rockville, MD 20852, USA
    AIDS 17:377-87. 2003
    ..To examine temporal variation in the effects of CCR5-Delta32 and CCR2-64I chemokine receptor gene polymorphisms on HIV-1 disease progression...
  4. ncbi request reprint Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa
    Clive M Gray
    National Institute for Communicable Diseases, Johannesburg, South Africa
    AIDS Res Hum Retroviruses 21:285-91. 2005
    ....
  5. pmc Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection
    Tara M Riddle
    UNC Center for AIDS Research, University of North Carolina at Chapel Hill, CB 7295, Chapel Hill, NC 27599 7295, USA
    J Virol 80:10591-9. 2006
    ....
  6. ncbi request reprint Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
    Punnee Pitisuttithum
    Vaccine Trial Center, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    J Acquir Immune Defic Syndr 37:1160-5. 2004
    ..Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1...
  7. ncbi request reprint High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion
    Eleanor Gouws
    Medical Research Council, Congella, South Africa
    J Acquir Immune Defic Syndr 29:531-5. 2002
    ..The HIV-1 incidence rates provide valuable additional information indicating that new infections are continuing unabated and that the HIV-1 epidemic is still growing in rural South Africa...
  8. pmc Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load
    Agatha Masemola
    National Institute for Communicable Diseases, Johannesburg, South Africa
    J Virol 78:3233-43. 2004
    ..These data have significance for the design of vaccines and for interpretation of vaccine-induced responses...
  9. ncbi request reprint Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Deborah Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 190:903-7. 2004
    ..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection...
  10. pmc Breast milk pasteurization: appropriate assays to detect HIV inactivation
    Caroline J Chantry
    Infect Dis Obstet Gynecol 2006:95938. 2006
  11. ncbi request reprint HIV type 1 subtype C gag and nef diversity in Southern Africa
    Helba Bredell
    Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa
    AIDS Res Hum Retroviruses 23:477-81. 2007
    ..We do not, however, find much evidence of intersubtype recombination in the Southern African genes, implying that the likelihood of vaccine failure due to the emergence of intersubtype recombinants is probably low...
  12. ncbi request reprint Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies
    Cecilia Rademeyer
    Institute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Observatory 7925, Cape Town, South Africa
    Virology 368:172-81. 2007
    ..Collectively these data provide some insights into design features of an envelope immunogen aimed at inducing neutralizing antibodies...
  13. pmc Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002
    Carmem A de Freitas Oliveira
    Seção de Sorologia, Instituto Adolfo Lutz Secretaria de Estado da Saúde de São Paulo, Av Dr Arnaldo 351, 10 degree andar, 01246 902 São Paulo, Brazil
    J Clin Microbiol 43:1439-42. 2005
    ..2 per 100 pregnant women per year (95% confidence interval, 0.041 to 0.608). Western blot profiles suggested an association between results of the STARHS analysis and gp41/gp31 bands...
  14. ncbi request reprint Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa
    Agatha M Masemola
    National Institute for Communicable Diseases, University of Witwatersrand, Johannesburg, South Africa
    J Immunol 173:4607-17. 2004
    ....
  15. ncbi request reprint High incidence and prevalence of HIV-1 infection in high risk population in Calcutta, India
    Phalguni Gupta
    Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    Int J STD AIDS 14:463-8. 2003
    ..Such a high annual seroincidence rate makes this population well suited for studies of HIV-1 prevention, including vaccine trials...
  16. ncbi request reprint Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection
    Bhupat D Rawal
    Blood Centers of the Pacific, San Francisco, California 94118, USA
    J Acquir Immune Defic Syndr 33:349-55. 2003
    ..These results support the potential use of the Vironostika-LS EIA for detection of recent HIV-1 infections for incidence projections and for other epidemiologic, clinical, and molecular surveillance applications...
  17. ncbi request reprint Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection
    Stephanie Planque
    Chemical Immunology Research Center, Department of Pathology and Laboratory Medicine and Hemophilia and Thrombophilia Center, University of Texas Houston Medical School, Houston, Texas 77030, USA
    AIDS Res Hum Retroviruses 23:1541-54. 2007
    ..The neutralizing activity was specifically inhibited by an electrophilic inhibitor of the catalytic activity. The existence of catalytic IgAs to gp120 in uninfected humans suggests their role in resistance to HIV...

Research Grants2

  1. Whole Inactivated HIV-1; Stabilization and Immunogenicity
    Haynes Sheppard; Fiscal Year: 2007
    ..Therefore, this proposal represents a critical step in qualifying this HIV vaccine concept for transition from pre-clinical to clinical studies. ..